VolitionRx (NYSE:VNRX) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report report published on Tuesday. The brokerage issued a sell rating on the stock.

Separately, Cantor Fitzgerald reissued an overweight rating and issued a $2.50 price target on shares of VolitionRx in a research report on Thursday, May 16th.

VolitionRx Stock Down 6.5 %

Shares of VolitionRx stock opened at $0.68 on Tuesday. The company has a market capitalization of $56.32 million, a P/E ratio of -1.48 and a beta of 1.26. The company has a 50 day moving average of $0.76 and a 200 day moving average of $0.84. VolitionRx has a 52-week low of $0.55 and a 52-week high of $1.79.

VolitionRx (NYSE:VNRX) last issued its earnings results on Monday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.27 million. As a group, research analysts anticipate that VolitionRx will post -0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC purchased a new position in shares of VolitionRx Limited (NYSE:VNRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx as of its most recent SEC filing. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.